BMY

HOLD

Bristol-Myers Squibb Company

Healthcare · Rank #5 · Analyzed Oct 18, 2026

$59.75

Current Price

$150.37

Intrinsic Value

low confidence

Upside/Downside

9.6/10

Score

3.5/5

Quality

Analysis Summary

Valuation Consensus1/2 methods agree

Quality Score3.5/5.0

Framework RatingHOLD

Price vs Intrinsic ValueLow confidence — see rating

Fair Value Range

Low$29.87

Base (IV)$150.37

High$550.57

Entry Points

Conservative$20.91

Moderate$29.87

Aggressive$105.26

⚠️ Warnings

DCF/EPV diverge 13.1x — earnings power and cash flow disagree; fair value is low-confidence (blended conservatively)

Quality & Moat Breakdown

Return on Equity46.6% → 1.0/1.0

Debt LevelD/E 202 → 0/1.0

Revenue QualityGrowth 0.0%, margin Δ-0.6% +recovery → 0.5/1.0

Moat Strength4.5/5 → 1.0/1.0

Profit Margins18.9% → 1.0/1.0

Methodology

This analysis uses a unified valuation framework combining three methods, Discounted Cash Flow (3-scenario), Earnings Power Value, and Asset Valuation, with a quality scoring overlay. A stock needs 2/3 valuation methods to agree and a quality score ≥ 3.5/5 for a BUY rating.

Learn how this framework works →

This is a personal analysis tool, not financial advice. Do your own research before making investment decisions.